Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Validation of the RENISCHEM L-FABP POC Assay
Sponsor: Hikari Dx, Inc.
Summary
This study will involve measurement of levels of a novel urinary biomarker of renal ischemia, L-FABP. The purpose of the study is to perform a clinical validation of the ability of L-FABP measurements in urine using the RENISCHEM L-FABP POC Test to predict the development of AKI within 2 days following cardiac and vascular catheterization procedures involving exposure to radiocontrast media.
Official title: A Study of Contrast-induced Acute Kidney Injury Prediction Using the RENISCHEM L-FABP Assay at the Point-of-Care
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
450
Start Date
2021-10-01
Completion Date
2026-02
Last Updated
2026-02-25
Healthy Volunteers
No
Interventions
RENISCHEM L-FABP POC Test
Point-of-care test cassette with quantitative reader used for the measurement of L-type fatty acid binding protein (L-FABP) in human urine specimens.
Locations (6)
Chandler Regional Medical Center
Chandler, Arizona, United States
John Muir Health
Concord, California, United States
Clearwater Cardiovascular Consultants
Clearwater, Florida, United States
University of Florida at Jacksonville
Jacksonville, Florida, United States
Sinai Hospital of Baltimore
Baltimore, Maryland, United States
University of Oklahoma
Oklahoma City, Oklahoma, United States